Older patients with LBCL show comparable outcomes to younger patients and product-specific profiles in CAR-T therapy

Blood Immunology & Cellular Therapy 2026 Open access

Read full text
Authors: Sho Shibata, Yasuyuki Arai, Junya Kanda, Daisuke Kaji, Daisuke Minakata, Toshio Kitawaki, Kazuyuki Shimada, Tatsu Shimoyama, Satoshi Yoshihara, Shinichi Makita, Nobuharu Fujii, Go Yamamoto
+10 more Emiko Sakaida, Yasuhiro Nakashima, Akiyo Yoshida, Yoshihiro Umezawa, Jun Kato, Haryoon Kim, Keisuke Kataoka, Hideki Goto, Atsuta Yoshiko, Koji Kato
DOI: 10.1016/j.bict.2026.100037
Cited by: 0
References: 34

Abstract

Anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a key treatment option for patients with relapsed or refractory large B-cell lymphoma (LBCL). However, data on its effectiveness and safety in older populations remain limited, particularly in real-world clinical practice. Moreover, comparative outcomes among different CAR-T products across age groups have not yet been fully characterized. We conducted a nationwide retrospective cohort study using data from the Japanese Society for Transplantation and Cellular Therapy. A total of 908 patients who received CAR-T therapy between January 2019 and September 2024 were included. Patients were categorized as younger (aged

Fields of Study & Subjects

CAR-T cell therapy research Lymphoma Diagnosis and Treatment T-cell and B-cell Immunology

Publication details

Journal / source
Blood Immunology & Cellular Therapy
Volume
2
Issue
1
Pages
100037–100037
Publication date
28 January 2026
Language
EN